IN THE SPOTLIGHT

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

AstraZeneca’s Tagrisso gains approval in Canada for NSCLC

AstraZeneca’s Tagrisso gains approval in Canada for NSCLC

New treatment approved by Health Canada for people with lung cancer

New treatment approved by Health Canada for people with lung cancer

Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC

Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC

Tagrisso with chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Tagrisso with chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes

Osimertinib extends PFS by 3.2 years in LAURA

Osimertinib extends PFS by 3.2 years in LAURA